Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial-Reference-Cited by-同舟云学术

Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial

Published:2018-09-10 Issue:1 Volume:54 Page:87-95
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Takehara Tetsuo^ORCID,Sakamoto Naoya,Nishiguchi Shuhei,Ikeda Fusao,Tatsumi Tomohide,Ueno Yoshiyuki,Yatsuhashi Hiroshi,Takikawa Yasuhiro,Kanda Tatsuo,Sakamoto Minoru,Tamori Akihiro,Mita Eiji,Chayama Kazuaki,Zhang Gulan,De-Oertel Shampa,Dvory-Sobol Hadas,Matsuda Takuma,Stamm Luisa M.,Brainard Diana M.,Tanaka Yasuhito,Kurosaki Masayuki

Funder

Gilead Sciences

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/article/10.1007/s00535-018-1503-x/fulltext.html

Reference18 articles.

1. American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/ . Accessed 13 June 2018.

2. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649–59.

3. Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16:685–97.

4. Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618–28.

5. The Japan Society of Hepatology (JSH), Guidelines for the management of hepatitis C virus infection: edition 6.1, full version [Japanese]. 2018. http://www.jsh.or.jp/files/uploads/R1__6.pdf . Accessed 13 June 2018.

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatic arterial infusion of autologous CD34+ cells for hepatitis C virus-related decompensated cirrhosis: A multicenter, open-label, exploratory randomized controlled trial;Regenerative Therapy;2024-12

2. High-Fat Diet Delays Liver Fibrosis Recovery and Promotes Hepatocarcinogenesis in Rat Liver Cirrhosis Model;Nutrients;2024-08-01

3. Analysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors;Scientific Reports;2024-07-16

4. MicroRNA-223-3p levels in serum-derived extracellular vesicles predict regression of M2BPGi-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agents;Journal of Gastroenterology;2024-05-13

5. ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis;Journal of Gastroenterology;2024-05-10